文献速递肾小球疾病

激光显微切割联合质谱检测膜性肾病抗原的可靠临床方法

A reliable clinical test for detection of membranous nephropathy antigens using laser microdissection and mass spectrometry.
PubMed 文献 · Kidney Int · 2024-08-26

膜性肾病由抗原抗体免疫复合物沉积所致,已发现13种靶抗原覆盖80-90%病例。本研究开发基于激光显微切割的质谱法(LMD/MS),在75例已知抗原的MN中全部正确识别,在61例未知抗原中40例检出已知抗原,总体PLA2R阳性16.4%、其他抗原49.1%、未检出34.5%。

要点

  • LMD/MS可在石蜡肾活检组织中一站式检测多种MN抗原。
  • 在75例已知抗原的MN中,LMD/MS全部正确识别抗原。
  • 在61例未知抗原MN中,40例检出已知抗原,含多种少见抗原。

核心结论

  • LMD/MS是检测已知MN抗原的可靠方法,并可能提示未知抗原以促进发现。

研究设计与样本

  • 开发基于激光显微切割的质谱法(LMD/MS),使用石蜡包埋肾活检组织。
  • 分两步验证:75例已知抗原MN和61例未知抗原MN。

主要发现

  • 75例已知抗原MN中,LMD/MS全部正确识别抗原。
  • 61例未知抗原MN中,40例检出已知抗原,包括多种少见抗原。
  • 总体PLA2R检出16.4%,其他抗原49.1%,未检出34.5%。
  • 较低检出率与队列有意富集PLA2R阴性MN有关。

关键数值与推荐

  • 已发现13种MN靶抗原:PLA2R、THSD7A、EXT1和EXT2、NELL1、SEMA3B、NCAM1、CNTN1、HTRA1、FAT1、PCDH7、NTNG1、PCSK6和NDNF。
  • 这些抗原覆盖80-90%的MN抗原。
  • 目前IHC/IF可检测PLA2R、THSD7A、NELL1、SEMA3B和EXT1/EXT2,其余抗原无实用IHC/IF方法。

临床怎么用

  • LMD/MS可作为临床一站式检测MN抗原的方法,尤其适用于IHC/IF无法检测的抗原。
  • 准确识别MN抗原有助于关联其特征性临床病理表现。

局限性

  • 未知抗原队列有意富集PLA2R阴性MN,检出率低于预期。
  • 34.5%病例未检出上述已知抗原。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Membranous nephropathy (MN) results from accumulation of antigen-antibody immune complexes along the subepithelial region of the glomerular basement membranes. Over the last years, 13 target antigens have been discovered and include PLA2R, THSD7A, EXT1 and EXT2, NELL1, SEMA3B, NCAM1, CNTN1, HTRA1, FAT1, PCDH7, NTNG1, PCSK6 and NDNF, accounting for 80-90% of MN antigens. MN associated with many of these antigens have distinctive clinicopathologic findings. It is important to accurately identify the antigen in MN. Immunohistochemical (IHC) and/or immunofluorescence (IF) methods are currently used to detect PLA2R, THSD7A, NELL1, SEMA3B and EXT1/EXT2. However, for the remaining antigens, IHC/IF methods do not exist and are not practical for detection. Here, we developed laser microdissection-based mass spectrometry methodology (LMD/MS) as a one-stop clinical test for the detection of MN antigens using paraffin-embedded kidney biopsy tissue. The LMD/MS test was validated in two steps. LMD/MS was used to detect the antigen in 75 cases of MN with known antigens and correctly identified the antigen in all these cases. Next, LMD/MS was used to identify the antigen in 61 MN cases where the antigen was unknown and identified one of the known antigens in 40 of 61 cases including many of the less common antigens. This lower-than-expected detection rate is explained by intentional enrichment of the cohort with PLA2R-negative MN. Overall, PLA2R was identified in 16.4%, one of the other antigens detected in 49.1%, and in the remaining 34.5% of cases, none of the above antigens was detected. Thus, LMD/MS is an extremely useful and reliable method for the detection of known MN antigens and possibly indicating an unknown MN antigen for eventual discovery.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Vrana JA, Theis JD, Wegwerth PJ, et al. A reliable clinical test for detection of membranous nephropathy antigens using laser microdissection and mass spectrometry. Kidney Int. 2024. PMID: 39197586. doi:10.1016/j.kint.2024.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。